This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Arch Dermatol. 1990;126(10):1274.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Eosinophilia-myalgia syndrome (EMS) has been associated with consumption of L-tryptophan-containing products (LTCPs)^1,2 and most strongly associated with consumption of LTCPs produced by one manufacturer.^3-5 Epidemiologic and laboratory investigations have suggested that the implicated LTCPs were contaminated.^3-5 To further examine this hypothesis, CDC and the Food and Drug Administration (FDA) conducted additional laboratory studies. This report summarizes preliminary data that indicate that implicated LTCPs were contaminated with the ditryptophan aminal of acetaldehyde (DTAA).

The laboratory investigation determined that case-associated L-tryptophan (LT) cultures were negative for bacteria and viruses and that endotoxin levels were not elevated in caseassociated LT.⁶ Analysis of case-associated LT for 37 elements identified none at toxicologically significant concentrations.

Fifty lots of LT produced between March 1985 and June 1989 by the implicated manufacturer were analyzed by high-performance liquid chromatography (HPLC). Thirteen lots were linked to EMS cases; other lots were considered as controls because . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?